11/20
03:14 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
11/13
12:21 pm
axsm
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up [Yahoo! Finance]
Low
Report
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up [Yahoo! Finance]
11/13
08:05 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Robert W. Baird from $112.00 to $116.00. They now have an "outperform" rating on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Robert W. Baird from $112.00 to $116.00. They now have an "outperform" rating on the stock.
11/13
12:08 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/12
03:27 pm
axsm
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
11/12
02:05 pm
axsm
Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Transcript [Seeking Alpha]
Low
Report
Axsome Therapeutics, Inc. (AXSM) Q3 2024 Earnings Call Transcript [Seeking Alpha]
11/12
08:33 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $130.00 price target on the stock.
Medium
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $130.00 price target on the stock.
11/12
07:00 am
axsm
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
11/8
07:00 am
axsm
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
Low
Report
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024
10/29
07:00 am
axsm
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
Low
Report
Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024
10/15
06:15 pm
axsm
Axsome: AXS-07 And Its Upcoming Second PDUFA [Seeking Alpha]
Low
Report
Axsome: AXS-07 And Its Upcoming Second PDUFA [Seeking Alpha]
10/15
07:00 am
axsm
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
Low
Report
Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12
10/11
11:36 am
axsm
Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition? [Yahoo! Finance]
Low
Report
Will Auvelity & Sunosi Fuel Axsome's Growth Amid Stiff Competition? [Yahoo! Finance]
10/4
12:46 pm
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Royal Bank of Canada from $130.00 to $131.00. They now have an "outperform" rating on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its price target raised by analysts at Royal Bank of Canada from $130.00 to $131.00. They now have an "outperform" rating on the stock.
10/1
11:07 pm
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
9/29
07:38 am
axsm
1 Under-the-Radar Biotech Stock to Buy and Hold [Yahoo! Finance]
Low
Report
1 Under-the-Radar Biotech Stock to Buy and Hold [Yahoo! Finance]
9/24
07:13 am
axsm
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024 [Financial Post (Toronto, Ontario, Canada)]
Low
Report
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024 [Financial Post (Toronto, Ontario, Canada)]
9/24
07:00 am
axsm
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
Low
Report
Axsome Therapeutics Presents Data from Multiple Programs at Sleep Europe 2024
9/16
12:11 pm
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
9/6
11:04 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $107.00 price target on the stock.
9/5
08:07 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $130.00 price target on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $130.00 price target on the stock.
9/5
08:06 am
axsm
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
Low
Report
Axsome Therapeutics, Inc. (NASDAQ: AXSM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
9/4
01:32 pm
axsm
Why Is Axsome (AXSM) Up 4.8% Since Last Earnings Report? [Yahoo! Finance]
Low
Report
Why Is Axsome (AXSM) Up 4.8% Since Last Earnings Report? [Yahoo! Finance]
9/4
07:07 am
axsm
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine [Financial Post (Toronto, Ontario, Canada)]
Medium
Report
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine [Financial Post (Toronto, Ontario, Canada)]
9/4
07:00 am
axsm
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine
Medium
Report
Axsome Therapeutics Announces FDA Acceptance of NDA Resubmission for AXS-07 for the Acute Treatment of Migraine